IAAG
JAZZ icon

Innovative Asset Advisors Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Innovative Asset Advisors Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11
Closed -$2.08K – 656
2026
Q1 		$2.08K Buy
+11
New +$1.92K ﹤0.01% 896

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Innovative Asset Advisors Group's JAZZ Position: Q2 2026 in Review

Innovative Asset Advisors Group sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2026, closing a stake of 11 shares — an estimated $2.08K sold.

Innovative Asset Advisors Group first reported a position in JAZZ in Q1 2026 and held it in 1 quarter. The position peaked at $2.08K in Q1 2026. 602 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Innovative Asset Advisors Group reported no remaining Jazz Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Innovative Asset Advisors Group sold 11 Jazz Pharmaceuticals shares in Q2 2026, an estimated $2.08K.
  • Innovative Asset Advisors Group first reported a position in Jazz Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Innovative Asset Advisors Group's Jazz Pharmaceuticals position peaked at $2.08K in Q1 2026.
  • 602 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Innovative Asset Advisors Group's 13F filing for Q2 2026, filed 5 Aug 2026.